{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(5)"],"submitter":["Mooney AH"],"funding":["NHMRC","Callaghan Innovation","New Zealand Ministry of Business Innovation and Employment","Health Research Council of New Zealand"],"pubmed_abstract":["<h4>Background & aims</h4>Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a treatment strategy with potential for long-term effects. Here, we evaluated vaccines that induce the activity of type I natural killer T (NKT) cells to limit viral replication and license stimulation of conventional antiviral T-cells.<h4>Methods</h4>Vaccines were prepared by conjugating peptide epitopes to an NKT-cell agonist to promote co-delivery to antigen-presenting cells, encouraging NKT-cell licensing and stimulation of T cells. Activity of the conjugate vaccines was assessed in transgenic mice expressing the complete HBV genome, administered intravenously to maximise access"],"journal":["JHEP reports : innovation in hepatology"],"pagination":["101038"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11061331"],"repository":["biostudies-literature"],"pubmed_title":["Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells."],"pmcid":["PMC11061331"],"pubmed_authors":["Heath WR","Godfrey DI","Sette A","Guidotti LG","Tang C","Sidney J","Chisari FV","Anderson RJ","Giustini L","Farrand KJ","Hermans IF","Gulab SA","Painter GF","Mooney AH","Burn OK","Iannacone M","Di Lucia P","Fumagalli V","Compton BJ","Rava M","Bono E","Draper SL","Yuan W"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.","description":"<h4>Background & aims</h4>Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a treatment strategy with potential for long-term effects. Here, we evaluated vaccines that induce the activity of type I natural killer T (NKT) cells to limit viral replication and license stimulation of conventional antiviral T-cells.<h4>Methods</h4>Vaccines were prepared by conjugating peptide epitopes to an NKT-cell agonist to promote co-delivery to antigen-presenting cells, encouraging NKT-cell licensing and stimulation of T cells. Activity of the conjugate vaccines was assessed in transgenic mice expressing the complete HBV genome, administered intravenously to maximise access","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T23:38:09.245Z","creation":"2026-05-23T03:08:08.08Z"},"accession":"S-EPMC11061331","cross_references":{"pubmed":["38694959"],"doi":["10.1016/j.jhepr.2024.101038"]}}